{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Here is the number of recipients with non-serious adverse events assessed by the Common Toxicity Criteria version 2.0. A non-serious adverse event is any untoward medical occurrence.","groups":[{"description":"Recipients will receive induction chemotherapy with fludarabine, cyclophosphamide, etoposide, doxorubicin, vincristine, and prednisone. (one cycle is 5 days on drug therapy followed by a 16 day rest period). Prior to the transplant procedure, recipients will receive conditioning therapy followed by the infusion of donor stem cells.\n\nMethotrexate: Recipients will receive 4 doses of methotrexate by vein after the transplant to help prevent graft-versus-host disease (GVHD).\n\nCyclosporine: Recipients will receive cyclosporine by vein or by mouth for about 6 months after the transplant to help prevent graft-versus-host disease (GVHD).","id":"OG000","title":"Recipient"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Adverse events data were only collected for the recipients.","reportingStatus":"POSTED","timeFrame":"Date treatment consent signed to date off study, approximately 58 months and 13 days.","title":"Number of Recipients With Non-serious Adverse Events","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}